PharmiWeb12h
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
PharmiWeb12h
Sarclisa is the first anti-CD38 treatment approved…
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
Sanofi: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant Approval based on positive results from the IMROZ phase 3 study ...
Sanofi reports Q4 2024 increase in net income to $916m
Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...
Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript
Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...
manilatimes15h
Change in the total number of shares and votes in Anoto
The total number of shares and votes in Anoto as of 31 January 2025 amounts to 1,102,362,753. This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments ...